The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - AstraZeneca; Biothera; IGF Oncology; Martell diagnostic; Medtronic; Squarex Pharma; TTC Oncology; Vanquish Oncology
Consulting or Advisory Role - Biothera; TTC Oncology; Tychon; Vanquish Oncology
Research Funding - Lilly (Inst); Merck (Inst)
 
Xiaofei F. Wang
No Relationships to Disclose
 
Lin Gu
No Relationships to Disclose
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; G1 Therapeutics; Genentech/Roche; Novartis; Regeneron; Takeda
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Takeda (Inst)
 
Robert Arthur Kratzke
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Biolumina; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
 
Hedy L. Kindler
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; ERYTECH Pharma; Five Prime Therapeutics; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Roche/Genentech (Inst); Verastem (Inst)